Spherix Global Insights Delivers Cheeriodicals to Dialysis Patients
[Exton, PA., January 18, 2024]—Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages to dialysis patients at local dialysis clinics in West Chester and Phoenixville, PA. A team of nearly approximately 60 employees from Spherix Global Insights came together to volunteer their time, packing 200 Cheeriodicals care bags for patients […]
Lupus drug market growing as physicians adopt newer options — and look for more, research finds
With three relatively new drugs, plus a busy pipeline in both systemic lupus erythematosus (SLE) and lupus nephritis (LN), the lupus market has been taking off. The LN arena is especially busy now with two competitors gaining steam, but SLE is also on physicians’ minds with the potential for CAR-T cell therapy treatment on the […]
Potential for new Huntington’s treatment sparks optimism for MDs
But US neurologists also express frustration with current lack of therapies Neurologists in the U.S. are optimistic about the potential for a new treatment for Huntington’s disease, but emphasize the need for therapies that halt nerve degeneration before symptom onset, according to a report by Spherix Global Insights. Most of the specialist physicians surveyed hoped for a […]
US neurologists favorably view BTK inhibitors as potential MS therapies
But Spherix surveys across 2023 may not reflect recent setbacks in clinical trials More than one-third of neurologists in the U.S. believe Bruton’s tyrosine kinase (BTK) inhibitors could be of pivotal significance as a future treatment of multiple sclerosis (MS), according to findings of a recent Spherix Global Insights’ survey. “Through Spherix’s quarterly RealTime Dynamix market tracker, neurologists and […]
“I Need to See It With My Own Eyes”: How US Ophthalmologists React to Apellis’ Syfovre Safety Warnings When Managing Geographic Atrophy
Ophthalmologists’ reservations about using Syfovre in Geographic Atrophy are more limited to “new start” patients, according to Spherix Global Insights. [Exton PA, December 14, 2023] — Geographic Atrophy (GA), the most severe stage of dry age-related macular degeneration (dAMD), poses a significant challenge as retinal cells atrophy, resulting in irreversible lesions that impact central vision. […]
U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights. [Exton PA, December 13, 2023] — Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS). These BTKis, administered orally, possess the advantage of easy dosing while leveraging their […]
FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice’s VAFSEO (vadadustat), Prepares for Launch in Early 2024.
EVRENZO’s advantages of being first-to-market and possessing a broader label are likely to be key factors influencing VAFSEO uptake, according to the latest update from Spherix Global Insights. [Exton, PA., December 8, 2023]– EVRENZO made history as the initial hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive EU approval in August 2021, securing its position […]
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
US dermatologists’ perceptions and experience with Sotyktu likely impacting their take on the entire TYK2 class for the treatment of plaque psoriasis. Exton, PA., December 7, 2023 – While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call, practicing dermatologists in Spherix research highlight […]
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
Spherix Global Insights find JAK inhibitors, led by AbbVie’s Rinvoq, establishing significant footholds in both first and later line UC treatment. [Exton PA, November 30, 2023] – With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment, challenging established alternative mechanism […]
Eli Lilly’s Olumiant and Pfizer’s Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market lead over Litfulo. [Exton PA, November 15, 2023] — Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK inhibitors has […]
